Eternygen
Berlin
About Eternygen
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2017)
- Website: eternygen.de
- Phone: 49 30 1207 6983 0
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/eternygen-79843 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.